L-Aminoacyl-triazine Derivatives Are Isoform-Selective PI3Kβ Inhibitors That Target Nonconserved Asp862 of PI3Kβ

被引:27
|
作者
Pinson, Jo-Anne [1 ]
Zheng, Zhaohua [1 ]
Miller, Michelle S. [1 ]
Chalmers, David K. [1 ]
Jennings, Ian G. [1 ]
Thompson, Philip E. [1 ]
机构
[1] Monash Univ, Monash Inst Pharmaceut Sci, Parkville, Vic 3052, Australia
来源
ACS MEDICINAL CHEMISTRY LETTERS | 2013年 / 4卷 / 02期
基金
美国国家卫生研究院; 英国医学研究理事会;
关键词
PI3; kinase; p110; beta; ZSTK474; cancer; ANTITUMOR-ACTIVITY; CLASS-I; 3-KINASE; DISCOVERY; SERIES; OPTIMIZATION; PHOSPHATASE; CAL-101; PATHWAY; MODELS;
D O I
10.1021/ml300336j
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
A series of aminoacyl-triazine derivatives based upon the pan-PI3K inhibitor ZSTK474 were identified as potent and isoform-selective inhibitors of PI3K beta. The compounds showed selectivity based upon stereochemistry with L-amino acyl derivatives preferring PI3K beta, while their D-congeners favored PI3K delta. The mechanistic basis of this inhibition was studied using site-directed mutants. One Asp residue, D862, was identified as a critical participant in binding to the PI3K beta-selective inhibitors, distinguishing this class from other reported PI3K beta-selective inhibitors. The compounds show strong inhibition of cellular Akt phosphorylation and growth of PTEN-deficient MD-MBA-468 cells.
引用
收藏
页码:206 / 210
页数:5
相关论文
共 50 条
  • [1] PI3K Isoform-Selective Inhibitors in Cancer
    Duncan, Leslie
    Shay, Chloe
    Teng, Yong
    SINGLE-CELL SEQUENCING AND METHYLATION: METHODS AND CLINICAL APPLICATIONS, 2020, 1255 : 165 - 173
  • [2] Isoform-Selective PI3K Inhibitors for Various Diseases
    Bheemanaboina, Rammohan R. Y.
    CURRENT TOPICS IN MEDICINAL CHEMISTRY, 2020, 20 (12) : 1074 - 1092
  • [3] Discovery of novel quinazolinone derivatives as high potent and selective PI3Kδ and PI3Kδ/γ inhibitors
    Ma, Chen-Chen
    Zhang, Cheng-Mei
    Tang, Long-Qian
    Liu, Zhao-Peng
    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2018, 151 : 9 - 17
  • [4] Improving the Armamentarium of PI3K Inhibitors with Isoform-Selective Agents: A new Light in the Darkness
    Rodon, Jordi
    Tabernero, Josep
    CANCER DISCOVERY, 2017, 7 (07) : 666 - 669
  • [5] PI3K isoform-selective inhibitors: next-generation targeted cancer therapies
    Xiang Wang
    Jian Ding
    Ling-hua Meng
    Acta Pharmacologica Sinica, 2015, 36 : 1170 - 1176
  • [6] PI3K isoform-selective inhibitors: next-generation targeted cancer therapies
    Wang, Xiang
    Ding, Jian
    Meng, Ling-hua
    ACTA PHARMACOLOGICA SINICA, 2015, 36 (10) : 1170 - 1176
  • [7] Isoform-selective PI3K inhibitors as novel therapeutics for the treatment of acute myocardial infarction
    Doukas, J.
    Wrasidlo, W.
    Noronha, G.
    Dneprovskaia, E.
    Hood, J.
    Soll, R.
    BIOCHEMICAL SOCIETY TRANSACTIONS, 2007, 35 : 204 - 206
  • [8] Isoform-selective targeting of PI3K: time to consider new opportunities?
    Cirillo, Davide
    Diceglie, Marta
    Nazare, Marc
    TRENDS IN PHARMACOLOGICAL SCIENCES, 2023, 44 (09) : 601 - 621
  • [9] Designing selective PI3K inhibitors
    Crunkhorn, Sarah
    NATURE REVIEWS DRUG DISCOVERY, 2010, 9 (02) : 105 - 105
  • [10] Designing selective PI3K inhibitors
    Sarah Crunkhorn
    Nature Reviews Drug Discovery, 2010, 9 : 105 - 105